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| INTRODUC TI ON
Donor-specific antibodies (DSAs) are a major trigger of allograft injury.
1 Active antibody-mediated rejection (ABMR) is characterized by immune cell recruitment in the microvasculature-in kidney transplant peritubular capillaritis (ptc) and/or glomerulitis (g)-which may proceed to chronic injury, graft dysfunction, and loss. [2] [3] [4] The exact mechanisms that promote inflammation are elusive. Alloantigenbound DSA may trigger activation of the classical complement cascade, which may promote endothelial cell activation and attraction of immune cells. 5, 6 DSA, however, may cause harm also independently of complement, mediated via the interaction between the IgG Fc portion and Fc gamma receptors (FcγRs) variably expressed on immune cells. 7, 8 FcγR signaling may initiate a variety of effector mechanisms contributing to graft injury, such as immune cell recruitment and activation, and release of cytokines, reactive oxygen species, or cytotoxins. 7, 8 A series of gene polymorphisms were shown to modulate the affinity and/or functionality of activating FcγR, independently of receptor expression. 9 and IgG3 and to influence immune cell activation. [12] [13] [14] Moreover, FcγRIIIB, which is expressed mainly on neutrophils, comprises the so-called neutrophil antigen (NA) system, which includes 2 isoforms, NA1 and NA2: 1 synonymous and 4 nonsynonymous mutations led to 4 amino acid differences affecting N-linked glycosylation and, as a consequence, receptor function. 10, 12 A variety of studies support the clinical relevance of functional FcγR polymorphisms. Distinct allelic variants were suggested to increase the risk for autoimmune disease [14] [15] [16] and influence the responsiveness to therapeutic antibodies 17, 18 and infection risk. 19 There are few data on the role of FcγR polymorphisms in transplantation. In experimental models, FCGR2A-H/H 131 monocytes were found to adhere more readily to HLA IgG-activated endothelial cells. 20 Clinical studies evaluating functional FcγRIIA polymorphisms in relation to transplant outcomes, however, have revealed controversial results. [21] [22] [23] [24] [25] [26] FcγRIIIA polymorphisms were suggested to influence the efficacy of depleting antilymphocyte antibodies, 18 but a small study of pediatric recipients failed to demonstrate associations of FcγRIIIA (and FcγRIIIB) variants with rejection. 25 Finally, in a recent large study, Clatworthy et al 27 showed that de-functioning variants of inhibitory FcγRIIB were not associated with long-term transplant outcomes.
Until now, there were no data available linking functional variants of activating FcγR with the morphologic and molecular presentation of ABMR. We speculated that high-activity FcγR variants enhance the ability of DSA to trigger inflammation, and thus promote rejec- 
| MATERIAL S AND ME THODS

| Study design and participants
Patients were recruited at the Medical University of Vienna in the context of the BORTEJECT trial (ClinicalTrials.gov: NCT01873157). 28, 29 As shown in Figure 1 , study subjects were identified by cross-sectional ABMR screening of 741 prevalent adult patients in outpatient care (screening period from October 2013 through February 2015). Key inclusion criteria were a functioning allograft ≥180 days posttransplantation and an estimated GFR (eGFR) of ≥20 mL/min/m 2 . ABMR screening revealed 111 DSApositive recipients, of which 86 underwent transplant biopsies. For 85 subjects, adequate material for FcγR genotyping was available, and they were included in the present study ( Figure 1 ). Baseline data are provided in Table 1 . A group of 213 healthy randomly se- 
| Antibody detection
As earlier described in detail, 28 we used LABscreen Single Antigen assays (One Lambda, A Thermo Fisher Scientific Brand, Canoga Park, CA) to characterize HLA reactivity patterns. Serum samples were heat-inactivated to counteract complement interference.
30
The presence or absence of DSA (mean fluorescence intensity [MFI] threshold >1000) was determined in the context of serological and/ or low-or high-resolution donor/recipient HLA typing (HLA-A, -B, -Cw, -DR, -DQ, and/or DP). Test results were documented as the MFI of the immunodominant DSA (MFI_max). 28 The complement (C1q)-binding ability of DSA was assessed using C1qScreen assays (One Lambda; MFI threshold >500).
| Biopsies
Histomorphology and C4d staining were evaluated on formalin-fixed paraffin-embedded sections. Multilayering of basement membranes of peritubular capillaries (MLPTCs) was assessed using electron microscopy. For microarray-based molecular analysis of biopsy samples, a fraction of one biopsy core was used for gene expression analysis as described previously. 31 A classifier related to ABMR (molecular ABMR score) was generated using a reference set of 1208 biopsy specimens. 32 We also evaluated various pathogenesis-based transcript (PBT) scores representing major biological events derived from experimental cell culture studies, mouse transplant studies, and human kidney transplants. 33 
| Fc receptor genotyping
Genomic DNA was isolated from frozen ethylenediaminetetraacetic acid-anticoagulated whole blood with a column-based method using Variables with a P < .15 were included in multivariable binary lo- 
| RE SULTS
The study included 85 DSA-positive kidney transplant recipients subjected to protocol biopsies (study flow chart: see Figure 1 ). As detailed in Table 1, FcγR genotypes, are shown in Table 3 . 
| Distribution of FcγR variants
| FcγR variants, DSA characteristics, and biopsy results
As shown in Table 3 , FcγR genotypes were not associated with DSA characteristics. FcγRIIIA genotypes containing the high-affinity V 158 variant, however, were associated with microcirculation inflammation ( .23
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homozygotes and heterozygotes (Suppl. Table S1 ). As detailed in V 158 individuals showed a trend toward higher molecular ABMR scores (Table 4 ). In parallel, distinct PBTs-QCMAT (quantitative constitutive macrophage-associated transcripts), AMAT1 (alternative macrophage activation-associated transcripts), and IRRAT (injuryrepair response-associated transcript) scores-were higher, albeit not significant after false discovery rate (FDR) correction ( Figure 2 , Table S2 ). Differences in other tested PBTs, including NKB (NK cell burden), ENDAT (endothelium-associated transcripts), eDSAST (endothelial DSA-selective transcripts), GRIT1 (γ-interferon associated transcripts), or IRIT3 (injury and repair-induced transcripts peaking at day 3) were not significant ( Figure 2 ).
Relating to FcγRIIA and FcγRIIIB genotypes, differences in biopsy findings were not significant, although there was a trend toward higher ptc scores in patients with high-affinity FcγRIIA variants (Table 4, Table S1 ). PBTs were not different (Table S2) .
Finally, we evaluated the combined effect of multiple highfunctional FcγR variants (Table S3) . Forty-seven patients had ≥1 copy of each FCGR2A-H 131 and FCGR3A-V 158 alleles. The rate and extent of ptc's were significantly higher in these recipients, but differences were similar to those seen in the FcγRIIIA alone analysis. Differences in other biopsy results remained nonsignificant.
Similarly, combined analysis of 3 different high-functional alleles (FCGR2A-H 131 , FCGR3A-V 158 , and FCGR3B-NA1) also failed to associate with increased microcirculation inflammation (Table S3 ).
| FcγR variants and allograft outcome
FcγRIIA, FcγRIIIA, and FcγRIIIB genotype groups were similar regarding eGFR levels at 12 and 24 months (Table 5 ). In addition, no For 2 and 4 recipients, biopsy material was not sufficient for ptc and g scoring, respectively.
c For 3 recipients, biopsy material was not sufficient for cg scoring.
d
Material for ultrastructural analysis was not preserved for 3 recipients.
e Gene expression analysis was performed in 82 of the 85 patients.
TA B L E 3 (Continued)
function or protein excretion, but patients with both high-functional FCGR2A and FCGR3A alleles showed better overall graft survival.
| Functional implications of NK cell FcγR variants
Given the associations found with FCGR3A-V 158 alleles, we sought to examine the functional implications of this polymorphism on NK cell 
| D ISCUSS I ON
In this study, we investigated whether recipient FcγR gene variants ABMR, antibody-mediated rejection; CI, confidence interval; DSA, donor-specific antibody; CDC, complement-dependent cytotoxicity; FcγR, Fc gamma receptor; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin; OR, odds ratio; ptc, peritubular capillaritis. a Multivariable binary logistic regression models included variables with a P value <.15 in univariable analysis. Because of a tight association between "C4d in peritubular capillaries" and "C1q-binding DSA," we performed 2 independent models (multivariable models 1 and 2), each excluding 1 of these 2 variables. 54 .67
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Protein/creatinine ratio (mg/g) The lack of association for FCGR3B variants with any of the parameters examined is not unexpected. This receptor is exclusively expressed by human neutrophils, which are rarely observed in late ABMR. Furthermore, although FcγRIIIB shows the same preferences for human IgG as FcγRIIIA, a key structural difference is that FcγRIIIB is a GPI-linked receptor that lacks a dedicated signaling component. 12 As a result, the biological role of FcγRIIIB remains incompletely understood. IFN-γ levels in culture supernatants were measured by enzymelinked immunosorbent assay at the time points indicated. Data points represent the average values of the assay performed against T cell targets purified from 3 healthy volunteers, each performed in triplicate. Repeated measures were analyzed using 2-way analysis of variance (ANOVA) (*P < .001) detection of subtle differences in the long-term course of allograft function and survival. In this respect, we want to point out the pilot character of our study, which, however, may provide a valuable basis for larger studies to decipher the impact of FcγR polymorphisms on long-term graft outcomes.
In conclusion, our data suggest that the FcγRIIIA V 158 high-affinity allele enhances the ability of anti-HLA DSA to trigger inflammation in the microcirculation, independent of complement activation. These results need confirmation in independent populations, and future studies will need to clarify whether our findings translate into adverse long-term allograft outcomes in large transplant cohorts.
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